Clinical Trial

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Name: A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) — clinical trial record (NCT06449651)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FREESIA-1

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Trial Details

NCT Number	NCT06449651
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Thrombocytopenia, Neonatal Alloimmune
Enrollment	39 participants
Start Date	2024-11-11
Primary Completion	2029-12-05 (estimated)
Study Completion	2029-12-05 (estimated)
Updated on ClinicalTrials.gov	2026-07-06